Similarly, downregulation of miR-181 was responsible for resistance to imatinib by directly targeting the Bcl-2 family member Mcl-1 in chronic myelogenous leukemia cells [16]. This evidence concerns the gene BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive.